Literature DB >> 21647537

Effect of oxygen levels on the physiology of dendritic cells: implications for adoptive cell therapy.

Diahnn Futalan1, Chien-Tze Huang, Ingo G H Schmidt-Wolf, Marie Larsson, Davorka Messmer.   

Abstract

Dendritic cell (DC)-based adoptive tumor immunotherapy approaches have shown promising results, but the incidence of tumor regression is low and there is an evident call for identifying culture conditions that produce DCs with a more potent Th1 potential. Routinely, DCs are differentiated in CO(2) incubators under atmospheric oxygen conditions (21% O(2)), which differ from physiological oxygen levels of only 3-5% in tissue, where most DCs reside. We investigated whether differentiation and maturation of DCs under physiological oxygen levels could produce more potent T-cell stimulatory DCs for use in adoptive immunotherapy. We found that immature DCs differentiated under physiological oxygen levels showed a small but significant reduction in their endocytic capacity. The different oxygen levels did not influence their stimuli-induced upregulation of cluster of differentiation 54 (CD54), CD40, CD83, CD86, C-C chemokine receptor type 7 (CCR7), C-X-C chemokine receptor type 4 (CXCR4) and human leukocyte antigen (HLA)-DR or the secretion of interleukin (IL)-6, tumor necrosis factor (TNF)-α and IL-10 in response to lipopolysaccharide (LPS) or a cytokine cocktail. However, DCs differentiated under physiological oxygen level secreted higher levels of IL-12(p70) after exposure to LPS or CD40 ligand. Immature DCs differentiated at physiological oxygen levels caused increased T-cell proliferation, but no differences were observed for mature DCs with regard to T-cell activation. In conclusion, we show that although DCs generated under atmospheric or physiological oxygen conditions are mostly similar in function and phenotype, DCs differentiated under physiological oxygen secrete larger amounts of IL-12(p70). This result could have implications for the use of ex vivo-generated DCs for clinical studies, since DCs differentiated at physiological oxygen could induce increased Th1 responses in vivo.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21647537      PMCID: PMC3188869          DOI: 10.2119/molmed.2011.00031

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  41 in total

Review 1.  Exploiting dendritic cells to improve vaccine efficacy.

Authors:  Ralph M Steinman; Melissa Pope
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

2.  Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial.

Authors:  Wei-Chen Lee; Hui-Chuan Wang; Chien-Fu Hung; Pei-Fang Huang; Chen-Rong Lia; Miin-Fu Chen
Journal:  J Immunother       Date:  2005 Sep-Oct       Impact factor: 4.456

3.  Culturing at atmospheric oxygen levels impacts lymphocyte function.

Authors:  Kondala R Atkuri; Leonard A Herzenberg; Leonore A Herzenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-28       Impact factor: 11.205

Review 4.  Dendritic cells: understanding immunogenicity.

Authors:  Ralph M Steinman
Journal:  Eur J Immunol       Date:  2007-11       Impact factor: 5.532

5.  Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA.

Authors:  S K Nair; D Boczkowski; M Morse; R I Cumming; H K Lyerly; E Gilboa
Journal:  Nat Biotechnol       Date:  1998-04       Impact factor: 54.908

6.  A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer.

Authors:  Alfred E Chang; Bruce G Redman; Joel R Whitfield; Brian J Nickoloff; Thomas M Braun; Peter P Lee; James D Geiger; James J Mulé
Journal:  Clin Cancer Res       Date:  2002-04       Impact factor: 12.531

7.  Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma.

Authors:  A Karolina Palucka; Madhav V Dhodapkar; Sophie Paczesny; Susan Burkeholder; Knut M Wittkowski; Ralph M Steinman; Joseph Fay; Jacques Banchereau
Journal:  J Immunother       Date:  2003 Sep-Oct       Impact factor: 4.456

Review 8.  Cancer immunotherapy with mRNA-transfected dendritic cells.

Authors:  Eli Gilboa; Johannes Vieweg
Journal:  Immunol Rev       Date:  2004-06       Impact factor: 12.988

Review 9.  Harnessing the immune system against human glioma.

Authors:  Kavita M Dhodapkar; Devi Banerjee; Ralph M Steinman
Journal:  Ann N Y Acad Sci       Date:  2005-12       Impact factor: 5.691

10.  Hypoxia skews dendritic cells to a T helper type 2-stimulating phenotype and promotes tumour cell migration by dendritic cell-derived osteopontin.

Authors:  Meixiang Yang; Chunhong Ma; Shuxun Liu; Jintang Sun; Qianqian Shao; Wenjuan Gao; Yan Zhang; Zewu Li; Qi Xie; Zhaogang Dong; Xun Qu
Journal:  Immunology       Date:  2008-10-21       Impact factor: 7.397

View more
  3 in total

1.  Our NIH years: a confluence of beginnings.

Authors:  Leonore A Herzenberg; Leonard A Herzenberg
Journal:  J Biol Chem       Date:  2012-10-12       Impact factor: 5.157

2.  When Cells Suffocate: Autophagy in Cancer and Immune Cells under Low Oxygen.

Authors:  Katrin Schlie; Jaeline E Spowart; Luke R K Hughson; Katelin N Townsend; Julian J Lum
Journal:  Int J Cell Biol       Date:  2011-11-29

Review 3.  Optimizing dendritic cell-based immunotherapy: tackling the complexity of different arms of the immune system.

Authors:  Ilse Van Brussel; Zwi N Berneman; Nathalie Cools
Journal:  Mediators Inflamm       Date:  2012-07-18       Impact factor: 4.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.